Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...

German science and technology company Merck lowered mid-term targets for its Life Sciences and Healthcare businesses, ...

Ken Frazier and Ken Chenault said companies retreating from DEI will limit equal opportunities for disadvantaged Americans.

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine ...